Boston Scientific Corp.'s Emblem subcutaneous implantable cardioverter defibrillator (S-ICD) earned FDA approval in 2013. In 2017 professional society guidelines were issued on the management of ventricular arrhythmias and the prevention of sudden cardiac death that recommend S-ICDs for some patients. However, many payers still consider it an "experimental" therapy for the purposes of coverage.
Boston Scientific added the S-ICD technology to its portfolio when it acquired Cameron Health in 2012. (Also see "Exec Chat: From Cameron To Boston Scientific, Navigating Through CRM Challenges"...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?